First Patients Dosed in Phase 2 Platform Clinical Trial Test

A phase 2 clinical trial testing novel immunotherapy combinations in aggressive ovarian cancer has opened and first patients have begun treatment.

Related Keywords

United States , New York , Memorial Sloan Kettering Cancer Center , University Of Chicago , Illinois , United Kingdom , Vancouver , British Columbia , Canada , Toronto , Ontario , Sunnybrook , Alberta , Chicago , Canadian , British , Helen Mackay , Kunle Odunsi , Audra Moran , Mecbotamab Vedotin , Ozuriftamab Vedotin , Jay Campbell , Dmitriy Zamarin , Ovarian Cancer Research Alliance , Venture Fund , Cancer Research Institute , University Of Chicago Comprehensive Cancer Center , Odette Cancer Center , National Academy Of Sciences , Scientific Advisory Council , Astrazeneca , Bioatla Inc , Division Of Medical Oncology , Canadian Cancer Trials Group , World Health Organization , Vancouver Centre , Cancer Research Institute Drug Selection Committee , Sunnybrook Health Sciences Centre , Platform Study , Anna Maria Kellen Clinical Accelerator , Cancer Research , Ovarian Cancer Research , Chicago Comprehensive Cancer Center , Medical Oncology , Medical Oncologist , British Columbia Cancer , National Academy , Maria Kellen Clinical , Cancer Research Alliance , Capitol Hill , Newswise , Varian Cancer Ovarian Research Alliance High Grade Serous Carcinoma Immunotherapy Checkpoint Blockade Kinase Inhibitor Antibody Drug Conjugate , Cancer , Clinical Trials , Obgyn , Womens Health , Cancer Center Featured Story 2 , Ancer Research Institute Cri And Ovarian Cancer Alliance Ocra ,